| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
2-Pyridinecarbohydrazide targets mycolic acid biosynthesis in Mycobacterium tuberculosis, making it a potential antitubercular agent. Mycolic acids are essential components of the mycobacterial cell wall, and inhibition of their biosynthesis disrupts cell wall integrity, leading to bacterial death. The compound’s hydrazide group is key to its biological activity, as it can form coordination complexes with metal ions or interact with enzymatic active sites. In addition to its antitubercular activity, 2-pyridinecarbohydrazide is a valuable intermediate for synthesizing antitumor agents, such as 1-acetyl-2-picolinoylhydrazine analogs. Its ability to chelate metal ions also makes it useful in coordination chemistry and catalysis research.
|
|---|---|
| ln Vitro |
2-Pyridinecarbohydrazide exhibits in vitro activity against Mycobacterium tuberculosis by inhibiting mycolic acid biosynthesis. The compound’s antitubercular activity is assessed using standard broth microdilution methods to determine the minimum inhibitory concentration (MIC) against M. tuberculosis strains. Its activity is attributed to its hydrazide functionality, which can interfere with enzymatic processes involved in cell wall synthesis. The compound is also used as an intermediate in the synthesis of various antitumor agents, and its derivatives have been evaluated for anticancer activity in vitro. These studies confirm the compound’s potential as a pharmacophore for drug development.
|
| ln Vivo |
In vivo activity of 2-pyridinecarbohydrazide has been less extensively studied, as the compound is primarily used as a synthetic intermediate rather than a therapeutic agent. However, its antitubercular activity suggests potential in vivo efficacy against mycobacterial infections. The compound’s derivatives have been evaluated in animal models for antitumor activity. Further in vivo studies would be needed to fully characterize its pharmacokinetic and pharmacodynamic properties. The compound’s primary value in research lies in its role as a versatile building block for the synthesis of more complex bioactive molecules.
|
| Enzyme Assay |
In vitro enzyme assays for 2-pyridinecarbohydrazide are not commonly performed, as the compound is primarily used as a synthetic intermediate rather than a direct enzyme inhibitor. However, when studying its antitubercular activity, assays may involve measuring its effect on mycolic acid biosynthesis in mycobacterial cell-free extracts. Radiolabeled precursors such as 14C-acetate are used to track mycolic acid synthesis, and the incorporation of label is measured in the presence and absence of the compound. These assays help elucidate the mechanism of action and confirm the compound’s target in the mycolic acid biosynthesis pathway.
|
| Cell Assay |
In vitro cellular assays for 2-pyridinecarbohydrazide are conducted in mycobacterial cultures to assess its antitubercular activity. M. tuberculosis or M. smegmatis is cultured in appropriate medium and treated with varying concentrations of the compound. Bacterial growth is monitored by optical density or colony counting. The minimum inhibitory concentration (MIC) is determined. Cytotoxicity assays in mammalian cell lines (e.g., Vero cells) are performed to assess selectivity. For antitumor applications, cancer cell lines are treated with derivatives of 2-pyridinecarbohydrazide, and cell proliferation and apoptosis are measured. These assays confirm the compound’s biological activity and guide further drug development.
|
| Animal Protocol |
In vivo animal experiments with 2-pyridinecarbohydrazide are not extensively documented, as the compound is primarily used as a research intermediate rather than a therapeutic agent. However, its antitubercular activity has been evaluated in mouse models of tuberculosis infection. Mice are infected with M. tuberculosis and treated with the compound or its derivatives via oral or parenteral administration. Bacterial load in lungs and spleen is measured, and survival is monitored. For antitumor studies, derivatives of 2-pyridinecarbohydrazide have been evaluated in xenograft models. These studies help define the in vivo efficacy and potential therapeutic applications of the compound and its derivatives.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 2-pyridinecarbohydrazide are limited, as the compound is primarily used as a synthetic intermediate rather than a drug candidate. It has a molecular weight of 137.14 and is soluble in organic solvents. Its small molecular size and hydrazide functionality suggest it could be orally bioavailable, but specific PK parameters have not been extensively reported. The compound’s stability in solution has rarely been reported. For research use, it is typically handled as a solid and stored under standard laboratory conditions. Further PK studies would be needed if the compound were to be developed as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
Toxicological data for 2-pyridinecarbohydrazide are limited. The compound is intended for research use only and is not approved for human therapeutic use. As a hydrazide derivative, it may have potential toxicity concerns, as some hydrazides are known to be hepatotoxic or genotoxic. However, comprehensive toxicological evaluations have not been extensively published. Standard laboratory safety precautions should be followed when handling this compound. Further toxicity studies would be required to support any potential clinical development. The compound should be handled with appropriate personal protective equipment.
|
| Additional Infomation |
2-Pyridinecarbohydrazide is a versatile building block and intermediate used in various fields of synthesis. It is also known as 2-pyridinecarboxylic acid hydrazide or picolinic acid hydrazide. The compound is used in the synthesis of antibiotics for the treatment of Mycobacterium tuberculosis and as an intermediate for antitumor agents. Its hydrazide functional group makes it a valuable precursor for the synthesis of hydrazones, acylhydrazines, and other bioactive compounds. The compound is also used in coordination chemistry and as a chelating ligand. It is available in high purity (≥98%) for research applications. Its versatility and small molecular size make it a useful tool in medicinal chemistry and drug discovery.
|
| Molecular Formula |
C₆H₇N₃O
|
|---|---|
| Molecular Weight |
137.14
|
| Exact Mass |
137.058
|
| CAS # |
1452-63-7
|
| PubChem CID |
255881
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Melting Point |
100°C
|
| Index of Refraction |
1.584
|
| LogP |
-0.83
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
10
|
| Complexity |
126
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1=C([H])C([H])=C([H])C([H])=N1)N([H])N([H])[H]
|
| InChi Key |
BAQLNPIEFOYKNB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H7N3O/c7-9-6(10)5-3-1-2-4-8-5/h1-4H,7H2,(H,9,10)
|
| Chemical Name |
pyridine-2-carbohydrazide
|
| Synonyms |
2Pyridinecarbohydrazide; 2 Pyridinecarbohydrazide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~729.18 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (18.23 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (18.23 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (18.23 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.2918 mL | 36.4591 mL | 72.9182 mL | |
| 5 mM | 1.4584 mL | 7.2918 mL | 14.5836 mL | |
| 10 mM | 0.7292 mL | 3.6459 mL | 7.2918 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
